All sponsors

Mirum Pharmaceuticals, Inc. $MIRM

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS9
PHASE 3 / 2-35
RECRUITING3
READOUTS ≤12 MONTHS4
READOUT SLIPPED >6 MO50%

Delay Index: of 6 active trials registered more than a year ago, 3 have moved their primary completion (readout) date by more than 6 months since first registration (median +23.0 months). See all sponsors →

Open Mirum Pharmaceuticals, Inc. on the live radar map → 📅 $MIRM readout calendar (.ics)
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
VISTAS
NCT04663308
P2Active, not recruitingPrimary Sclerosing Cholangitis1822026-02-20 (+39 mo)
Maralixibat
NCT06553768
P3Active, not recruitingCholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC)902026-07-29 (-1 mo)
Brelovitug 300 mg
NCT07298330
P3Active, not recruitingChronic Hepatitis D Infection802026-08
VANTAGE
NCT05050136
P2Active, not recruitingPrimary Biliary Cholangitis; PBC3332027-01 (+37 mo)
Brelovitug 300 mg
NCT07200908
P3RecruitingChronic Hepatitis D Infection1722027-06-30
Brelovitug (BJT-778)
NCT07454837
P2/3RecruitingChronic Hepatitis D1202027-08-31
Low dose of MRM-3379
NCT07209462
P2RecruitingFragile X Syndrome602027-10
OASIS
NCT07823127
P2Not yet recruitingIntrahepatic Cholestasis of Pregnancy152029-01-12
Brelovitug 300 mg
NCT06907290
P2/3Active, not recruitingChronic Hepatitis D Infection1502029-05 (+23 mo)